ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study

Results from the biomarker analysis from the JAVALIN Renal 101 clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week.

JAVELIN Renal 101 compared the avelumab plus axitinib combination with sunitinib. There were 886 patients in the study, 442 received the combination and 444 received sunitinib. For patients with PD-L1-positive tumours (560 patients, 63.2%), median progression-free survival was 13.8 months in patients receiving avelumab plus axitinib compared with 7.2 months with sunitinib. In the overall population, the median progression-free survival was 13.8 months with avelumab plus axitinib, compared with 8.4 months for sunitinib. Overall survival data are not yet complete.

During the study, the following four blood-based biomarker analyses were carried out:

  • PD-L1 expression (n=804)
  • CD8 expression (n=795)
  • A novel 26-gene JAVELIN gene signature (n=720)
  • Mutations and polymorphisms (n=733).

In summary:

These biomarkers could be used to determine treatment outcomes in advanced renal cell carcinoma (RCC) patients treated with a combination of immunotherapy plus a TKI in the first-line. These biomarkers may also be used to inform personalised therapy strategies for patients with advanced RCC. Work is ongoing to further investigate these findings.

Read more in UroToday here

Read more in OncLive here

Share this Post!

Related post